Skip to content


Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

What The Pharmas Are Reading

The latest issue of the Rx Compliance Report included  summaries of our posts, a flock of pharmas and why benchmarking matters.

We’re happy to be included. Most of the forty drug companies subscribe to the newsletter, as do the law firms that help them. For ten years, Rx Compliance has been chronicling the ‘government’s crackdown on pharmaceutical sales and marketing practices.’ That crackdown is gaining speed.

The Wall Street Journal reported this week that Pfizer will pay about $60 million to settle alleged FCPA violations. In April, Johnson & Johnson resolved FCPA offenses by paying $70 million.

Our 2011 corporate investigations list included Pfizer, as well as AstraZeneca, Biomet, Bio-Rad Laboratories, Bristol-Meyers Squibb, Covidien, Eli Lilly, GlaxoSmithKline, Medtronic, Merck, Orthofix International, Sciclone Pharmaceuticals, Smith & Nephew, Stryker Corporation, Talecris Biotherapeutics, and Zimmer.

The same issue of Rx Compliance ran a front-page story about Jeff Kaplan’s view of global enforcement trends. Kaplan, co-author of the anti-corruption compliance program benchmarking survey, also described ‘five practical benchmarks in anti-corruption efforts.’

Share this post


Comments are closed for this article!